EGFR and non-small cell lung carcinoma: To the best of our knowledge, this is the first analysis of patients with EGFR-mutated NSCLC who developed BM after receiving all the effective treatments, including first-generation TKIs as first line treatment, Osimertinib as subsequent therapy and brain RT.